The invasive nature of cancers in general, and malignant gliomas in particular, is a major clinical problem rendering tumors incurable by conventional therapies. Using a novel invasive glioma mouse model established by serial in vivo selection, we identified the p75 neurotrophin receptor (p75 NTR ) as a critical regulator of glioma invasion. Through a series of functional, biochemical, and clinical studies, we found that p75 NTR dramatically enhanced migration and invasion of genetically distinct glioma and frequently exhibited robust expression in highly invasive glioblastoma patient specimens. Moreover, we found that p75 NTR -mediated invasion was neurotrophin dependent, resulting in the activation of downstream pathways and producing striking cytoskeletal changes of the invading cells. These results provide the first evidence for p75 NTR as a major contributor to the highly invasive nature of malignant gliomas and identify a novel therapeutic target. 
Introduction
Malignant gliomas are diffuse, highly invasive, and often multifocal tumors that have a dismal prognosis, with a median survival of only 1 y and ''long-term survivors'' (i.e., surviving !3 y) are rare [1, 2] . A major barrier to effective malignant glioma treatment is their highly invasive nature; they extend tendrils of tumor several centimeters away from the main tumor mass, which render these tumors incurable by local therapies such as surgery or radiotherapy [3] . Ninetyfive percent of gliomas recur within 2.5 cm of the resection margin, which contains invasive cells that act as a ''disease reservoir'' and elude current treatments [4] . Glioma cells do this by becoming distinct from their noninvasive counterparts. Specifically, they activate a number of coordinate cellular programs, which include those necessary for migration (e.g., motility) and invasion (e.g., extracellular matrix degradation) [5] and also a number of pathways (e.g., reduced proliferation, marked resistance to apoptosis) [4, 6, 7] which render the invasive cells highly resistant to conventional treatments. A detailed understanding of the mechanisms underlying this invasive behavior is essential for the development of effective therapies.
Although in their infancy, attempts to identify genes involved in glioma invasion have used a number of techniques, including the isolation of invasive cells from human cell lines in vitro [6, 7] , the use of organotypic brain slice cultures [8] , and the collection of tumor and invasive cells from frozen glioblastoma patient specimens using laser capture microdissection [9] [10] [11] . Although each method has been successful in its own right, none of these models have been ideal or comprehensive for discovering the underlying mechanisms of invasion. New models or alternative strategies are needed. We have therefore undertaken the approach of serial in vivo selection to identify genes important for the invasive behavior of malignant glioma. Similar strategies have been used to effectively identify mechanisms underlying the metastatic behavior of both melanoma and breast tumors [12, 13] . Using this approach, we isolated highly invasive glioma cells from a relatively noninvasive human malignant glioma. Gene expression profiles comparing these two tumor cell populations identified the p75 neurotrophin receptor (p75 NTR ) as an important and potent mediator of invasion in human glioma. p75 NTR is a transmembrane glycoprotein and a member of the tumor necrosis factor (TNF) superfamily that was originally isolated as a nerve growth factor (NGF) receptor, but has since been shown to bind both the mature and precursor forms of the neurotrophin family of ligands (brainderived neurotrophin factor [BDNF] , neurotrophin-3 [NT-3], and neurotrophin-4/5 [NT-4/5]) [14] [15] [16] [17] [18] . In neurons, p75
NTR is coexpressed with a second group of neurotrophin receptors, the tropomysin receptor kinases (Trks). It has become increasingly clear that the dogma in neuroscience that Trks mediate neuronal survival and p75
NTR causes neuronal cell death is too narrow a view [19] [20] [21] [22] . Rather, there is a growing appreciation that p75 NTR , like other members in the TNF superfamily, mediates a very broad range of cellular functions, depending on the cell context and the repertoire of co-receptors that exist (e.g., Trks [23] , Nogo receptor [24] , and sortilin [25] ). In neurons, p75
NTR has been shown to increase [26, 27] or inhibit [28] axon growth, reduce [29] or promote [30, 31] neuronal cell death, and is either necessary [32] or not required [33] for inhibition of neuronal regeneration. These apparent discrepancies are not confined to neurons; p75 NTR has also been shown to both inhibit [34] and promote [26, 35] Schwann cell migration during development. Even though p75 NTR does not contain any catalytic activity, it interacts with several proteins that help transmit signals required for its various functions. Neurotrophin engagement of p75 NTR controls the activity of the small GTPase RhoA, providing a direct link from the receptor to modulating cellular architecture. As is the case for phenotypic responses, RhoA has been shown to be activated or inhibited depending on cellular context [27, 28, 34, [36] [37] [38] . Reports have hinted at roles for p75 NTR in growth [39] and apoptosis [40] of glioma cells; however, data presented here support a much different role for p75 NTR -that of mediating glioma cell invasion.
Results

Establishment of a Malignant Glioma Mouse Model to Study the Molecular Determinants of Glioma Invasion
One of the problems in xenotransplanting human glioma cells into the brains of immunocompromised mice is that the resulting tumors are circumscribed, with very little cell infiltration into the brain parenchyma [41] . To generate an orthotopic model that more closely mimics the human disease and allows for the identification of molecular determinants of glioma invasion in a global and unbiased manner, we used an in vivo-selection procedure to select for highly invasive human glioma cells ( Figure 1A ). We isolated highly invasive glioma cells from the noninvasive human malignant glioma cell line U87 expressing green fluorescent protein (GFP) (U87GFP) and a neomycin resistance gene. Expression of these genes afforded us the ability to isolate the rare glioma cell that migrated away from the primary tumor site. These ''invasive'' cells were grown and expanded in tissue culture, and reintroduced into the brains of immunocompromised mice where they formed highly infiltrative tumors with poorly defined edges ( Figure 1B ). These extremely invasive cells were found vast distances from the main tumor mass, with GFP-positive tumor cells readily identifiable in the contralateral hemisphere. In clear contrast, reimplantation of the noninvasive ''tumor'' cells led to the formation of large tumors with sharply demarcated edges ( Figure 1B ). Using this model, we identified gene expression differences between the noninvasive and highly invasive in vivo-selected glioma cells. RNA extracted from tumor and invasive populations was used to prepare labeled cDNA that was hybridized to 14,000-gene human oligonucleotide microarrays (produced by the Southern Alberta Microarray Facility, University of Calgary). Genes up-or down-regulated in the invasive population were compared to the tumor population, and genes that showed consistent gene expression changes of 2-fold or greater are outlined in Figure 2A . To ensure the integrity of the microarray data, we chose seven arbitrary genes for validation, the expression of five of which are shown in Figure 2B and 2C. Semiquantitative real-time polymerase chain reaction (RT-PCR) confirmed the expression of all seven genes, including granulocyte colony-stimulating factor (G-CSF), interleukin-8 (IL-8), DZFKp434B204 (unknown hypothetical protein), tissue inhibitor of metalloproteinases-3 (TIMP-3), and p75 NTR ( Figure 2B and 2C). The semiquantitative RT-PCR indicates that our microarray data is an underrepresentation of the fold changes in RNA expression. Based on the reproducibility of the data, previous implication in tumorigenesis in other cancers (e.g., melanoma and prostate) [42] [43] [44] [45] [46] [47] , and the novelty of the finding in brain tumors, we chose p75 NTR for further study. Importantly, we confirmed the up-regulation of p75 NTR was not only at the mRNA level, but that a dramatic alteration in abundance of p75 NTR was seen in the invading cells ( Figure 2C ). A number of invasive lines were generated by serial in vivo selection and microarray analysis using a second independent U87 invasive line validated the presence of p75 NTR by microarray that was confirmed by RT-PCR and Western blot (unpublished data). In addition, using the in vivo-selection paradigm outlined in Figure 1 , we isolated both tumor and invasive cells from a second human glioma cell line, U251N. These in vivo-selected invasive U251N cells also expressed high levels of endogenous p75 NTR ( Figure S1 ).
In Vivo Selection Identifies p75 NTR as a Mediator of Glioma Invasion
Although p75 NTR and its ligands, the neurotrophins, are expressed throughout the nervous system, particularly during development, a role for p75 NTR in central nervous system tumors has not been described previously. We therefore assessed whether the up-regulation of p75 NTR found in the invasive glioma cells had a functional consequence (i.e., increased their migration and invasion). The noninvasive and highly invasive cells were treated with the p75 NTR ligand NGF, and migration and invasion were measured. The addition of NGF to invasive cells significantly increased the number of cells able to invade through matrigel, but had no effect on the Author Summary
Gliomas are highly malignant and invasive tumors with tendrils that extend far from the primary tumor site, rendering conventional therapies ineffective and leading to an invariably poor prognosis. To understand the molecular mechanisms underlying this invasive behavior, we injected immunocompromised mice with human gliomas and compared invasive cells, which left the primary tumor site, to noninvasive cells, which remained at the site of injection. We identified the neurotrophin receptor p75 NTR -which normally functions during development to induce neurite outgrowth and promote neuronal cell death-as an important regulator of glioma invasion. We present the first evidence that this neurotrophin receptor can also be a potent mediator of glioma invasion, and we show that the expression of this receptor is sufficient to impart a dramatic invasive behavior on genetically distinct tumors. These data highlight a previously unknown function of this receptor and suggest it may be a novel therapeutic target in the treatment of this devastating cancer.
invasive ability of the tumor cells (which had no detectable p75 NTR ; Figure 2D ). Because neurotrophins are also ligands for the Trk receptors, RT-PCR and immunoprecipitation experiments were performed. No detectable mRNA or protein for the Trk receptors was found in the invading glioma cells (unpublished data). In addition, we tested the effect of the unprocessed or proform of NGF (pro-NGF), a high-affinity ligand for p75 NTR [33, 39] that is unable to activate Trk [16] . Accordingly, treatment of the invasive cells with cleavage-resistant pro-NGF enhanced their migration at concentrations as low as 1 ng/ml while having no effect on the tumor cells ( Figure S2 ). Although we found that neurotrophin could enhance invasion of the p75 NTR -positive invasive cells ( Figure 2D ), we also observed a significant increase in the absence of ligand. Signals from p75 NTR can arise both in the absence and presence of ligand; however, these signals often evoke opposing biological responses. Because the outcome of both neurotrophin-dependent and neurotrophin-independent signaling was the same, we considered the possibility that the glioma cells were producing and secreting neurotro- The noninvasive human glioma cell line U87 stably expressing GFP (U87GFP) was implanted into the brains of SCID mice. Four to 6 wk later, the mice were sacrificed. The ipsilateral side of the brain (containing a grossly visible tumor) was separated from the contralateral side (containing only isolated invasive glioma cells [i.e., no macroscopically visible GFP-labeled tumor]), and both were grown in culture. These noninvasive (tumor) and highly invasive glioma cells were reimplanted into additional mice, and the process was repeated to select for increasingly noninvasive or invasive glioma cells. RNA extracted from the resulting invasive and tumor populations was used to prepare labeled cDNA that was hybridized to oligonucleotide microarrays. phin(s), thus activating an autocrine loop. We assessed the expression of several neurotrophins and found that BDNF was present in both the conditioned media and the cell lysate of all glioma cells tested (unpublished data). Furthermore, we found that the presence of p75 NTR shifted the localization of BDNF from the conditioned media to the cell membrane ( Figure S3 ), supporting the notion of autocrine/paracrine activation of the p75 NTR receptor. To directly test the hypothesis that elevated expression of p75 NTR is necessary for neurotrophin-induced glioma migration and invasion, we surveyed a panel of human glioma cell lines for p75 NTR protein expression. We found that the human glioma cell line SF767 endogenously expressed high levels of p75 NTR , as detected by Western blot ( Figure 3A ) and fluorescence-activated cell-sorting (FACS) analysis (unpublished data). Using RNA interference (RNAi), we downregulated p75
NTR in the SF767 cell line using an expression vector containing a p75 NTR -specific small interfering ribonucleic acid (siRNA) and confirmed the down-regulation by RT-PCR and Western blot ( Figure 3A) . A random, nonspecific siRNA sequence was used as a control. Down-regulation of p75 NTR levels in SF767 was sufficient to reduce its migration in vitro and rendered the cells nonresponsive to addition of NGF in both migration and invasion assays ( Figure 3B and 3C). Similarly, down-regulation of p75 NTR by siRNA in the original in vivo-selected U87 invasive cells significantly blocked migration and invasion ( Figure S4 ).
Since down-regulation of p75 NTR in SF767 cells and U87 in vivo-selected invasive cells inhibited glioma invasion, we assessed whether ectopic expression of p75 NTR alone was sufficient to increase glioma migration and invasion in a cell line without detectable p75 NTR (the original U87 cell line). To this end, we stably transfected the full-length cDNA of human p75 NTR into the U87 glioma cell line, using stable transfection of the empty pcDNA vector as a control. Expression levels of p75 NTR in these cells were confirmed by RT-PCR and Western blot ( Figure 3D ). Expression of p75 NTR caused a significant increase in migration and invasion in vitro ( Figure 3E and 3F). Treatment of these cells with NGF had no further enhancement on their migration or invasion consistent with the idea that when p75 NTR is expressed, an autocrine loop is completed, leading to enhanced migration and invasion.
Expression of p75 NTR Increases Invasion In Vivo in Genetically Distinct Glioblastomas
Malignant gliomas clinically show extensive infiltration away from the main tumor and into the surrounding normal brain tissue. To determine whether the expression of p75 NTR was important for glioma cell invasion in vivo, we implanted the U87 human glioma cell line ectopically expressing p75 NTR into the brains of severe combined immunodeficiency (SCID) mice. U87 cells stably transfected with the empty pcDNA vector were implanted for comparison as a control. Twentyeight days after implantation, the mice were sacrificed and the brains prepared for immunohistochemical staining using antibodies directed against human nuclei and p75 NTR . Implantation of U87 glioma cells stably transfected with pcDNA led to the formation of well-circumscribed tumors that were p75 NTR negative ( Figure 4A ). In sharp contrast, implantation of U87 glioma cells stably expressing p75 NTR resulted in the formation of tumors with highly infiltrative edges ( Figure 4B ). Isolated p75 NTR -positive human glioma cells could be detected in regions vastly distant from the main tumor mass ( Figure S5 ).
Because malignant gliomas are an extremely heterogeneous group of tumors and the in vivo-selected U251N cells also expressed high levels of p75 ( Figure S1 ), we determined whether the sole expression of p75 NTR was sufficient to impart an invasive phenotype, not only on the U87 cells, but also on the genetically distinct U251N cells. U251N cells ectopically expressing p75 NTR (U251Np75), along with empty vector-transfected cells as a control (U251NpcDNA), were implanted into the brains of SCID mice as described above. As we have observed previously, the U251N control cell line (U251NpcDNA) was inherently more invasive than U87pcDNA in vivo, with finger-like projections extending from the main tumor mass into the surrounding normal brain (compare Figure 4A and 4C). Nevertheless, ectopic expression of p75 NTR (U251Np75) dramatically enhanced the inherent invasive ability, with p75 NTR -positive cells being found at locations distinct from the main tumor mass (compare Figure 4C and 4D). Thus, up-regulation of p75 NTR is sufficient to allow glioma cells of diverse genetic backgrounds to invade into the surrounding normal brain. Because p75 NTR can have effects on several physiological responses, we also evaluated the effect of p75 NTR expression on cell cycle, proliferation, and survival, and observed no significant change (unpublished data).
p75 NTR -Mediated Glioma Invasion Is Neurotrophin Dependent
In order to test whether neurotrophin was important in the invasive behavior of these cells, we constructed two p75 NTR mutants, p75CRD 105 and p75CRD 130 , containing a four-amino acid insertion in the cysteine-rich domain (CRD) following amino acids 105 and 130 (CRD 105 and CRD 130), respectively. Insertions at these locations disrupt the normal spacing of the cysteine residues within the164 ligand-binding domain and create p75
NTR proteins that are unable to bind to mature neurotrophin [48] . These constructs were stably transfected into U87 glioma cells, and cell surface expression for the mutant p75 NTR proteins was confirmed by FACS analysis ( Figure 5A ). To verify that the mutant p75 NTR do not bind neurotrophin, BDNF expression in the conditioned medium and total cell lysates of U87 cells expressing CRD these mutants do not bind endogenous BDNF ( Figure 5B ). These cells were implanted into the brains of SCID mice and allowed to grow for 21 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei ( Figure 5C ; brown color, top row) and human p75 NTR ( Figure 5C ; brown color, bottom row). Disruption of the neurotrophin binding capacity of p75
NTR results in tumors with well-defined borders similar to tumors formed by the parental U87 glioma cells that do not express p75 NTR . These data suggest that neurotrophin binding is required for p75 NTR -mediated glioma invasion.
p75 NTR -Expressing Glioma Cells from Human Glioma Surgical Specimens Show Enhanced Migration
The highly invasive nature of malignant gliomas has been a substantial barrier in the treatment of patients with this disease. Data presented here strongly suggest that p75 NTR , in a neurotrophin-dependent manner, is an important regulator of glioma invasion. To clinically validate p75 NTR 's role in glioma migration and invasion, and demonstrate its relevance in malignant glioma patient specimens, we analyzed the expression of p75 NTR in a panel of surgically resected 
p75 NTR Expression Results in Cytoskeletal Rearrangement and Changes in RhoA Activity
During the in vitro growth stage of the serial in vivoselection procedure, we observed that the invasive glioma cells had striking morphological differences to the ''tumor'' cells. To examine the morphology of these cells, fluorescent staining of the actin cytoskeleton was performed. Staining of the actin cytoskeleton using rhodamine phalloidin revealed cells with numerous filamentous protrusions present only in the invading population ( Figure 7A) . Similarly, we found that expression of p75 NTR alone induced structural rearrangement of the actin cytoskeleton similar to that of the in vivoselected invasive cells ( Figure 7B ). Because the small molecular weight GTPase RhoA is a potential downstream readout from p75 NTR that may help contribute to the distinct phenotype, we examined the effect of RhoA. Expression studies in HEK293 cells demonstrated that in the absence of ligand, p75 NTR constitutively activated Rho, whereas ligand binding leads to a decrease in the levels of active Rho [27] . In addition, Gehler et al. [49] have shown that neurotrophinbound p75 NTR induces growth cone filopodia through the modulation of RhoA and that neurotrophin binding is necessary and sufficient to regulate filopodia dynamics. We found that concomitant with the changes in actin cytoskeleton, cells expressing p75 NTR had reduced RhoA activity ( Figure 7C and 7D ).
Discussion
Human malignant gliomas are highly invasive tumors. This highly invasive nature associates theses tumors with an extremely poor prognosis owing to recurrence of the tumor outside the margin of therapeutic resection [50] . Invasion of glioma cells into the normal surrounding brain requires changes that make these cells distinct from their noninvasive counterparts. Specifically, these glioma cells activate a number of coordinate cellular programs that involve the regulation of many molecules, including adhesion molecules, extracellular matrix constituents, proteases, cytoskeleton components, and signaling molecules. Altered regulation of any of these constituents may lead to changes in glioma cell migration and invasion. Although numerous molecules have been implicated in the migration and invasion of gliomas, what triggers glioma cells to leave the main tumor mass and invade into the normal brain is not well understood. To this end, we have developed a serial in vivo-selection paradigm to isolate highly invasive glioma cells from a human glioma cell line that is noninvasive in xenotransplantation models. A similar approach has been used to successfully assess the global gene expression profile of both melanoma and breast cancer metastasis [7, 8] . Using this strategy, we identified and verified genes that were up-regulated in the invading glioma cells. One of the most differentially expressed genes encodes the neurotrophin receptor p75
NTR that is the focus of this study. We provide the first evidence both in vitro and in vivo that p75 NTR is a major mediator of glioma migration and invasion.
In recent years, there has been a growing importance of the neurotrophin signaling axis in cancer. Specifically, there is increasing evidence that the neurotrophic receptor tyrosine kinase TrkB, sometimes in conjunction with its primary ligand BDNF, is over-expressed in a variety of human cancers, ranging from neuroblastomas to pancreatic ductal adenocarcinomas [51] [52] [53] [54] [55] . Here, we present data that the panneurotrophin receptor p75 NTR is expressed in malignant glioma and is a major contributor to their highly invasive nature. Although a universal role for p75 NTR in cancer has not been established, recent studies implicate p75 NTR in the metastatic progression of melanoma, and specifically in those tumors that metastasize to the brain [43, 46, 56] . Conversely, p75 NTR expression has been linked to the progression of prostate cancer, but in this cancer, p75 NTR , which is expressed in normal prostate epithelia, is lost upon transformation [45] . The divergence observed in the tumor progression of these two distinct tumors can likely be explained by the presence of Trk. In prostrate tumor cells, Trk expression is retained and mediates proliferation [42, 57] , whereas p75
NTR -induced invasion in melanoma is independent of Trk expression [58] . Thus the recurring theme emerges that p75
NTR function is cell-type specific (even in cancer) and must be independently determined for each cellular context. Here, we have shown that p75 NTR -induced glioma invasion is also Trk independent with neither mRNA nor protein for the Trk receptors expressed by the invading glioma cells. Further supporting the Trk independence of p75 NTR -mediated glioma invasion is the finding that treatment of the invasive cells with cleavage-resistant pro-NGF (which cannot bind Trk; Figure S2 ) also enhanced the migration of invading glioma cells.
Tumor cells can survive by means of an autostimulatory (autocrine) signaling loop, such as that mediated by TrkB and BDNF, or through a paracrine cross-communication with their environment. In brain metastatic melanoma, normal brain tissue adjacent to the melanoma displays increased neurotrophin expression [56] , making it tempting to speculate that the metastatic melanoma uses the neurotrophinrich nervous system as a paracrine mediator of invasion. It has similarly not escaped our attention that the neurotrophin environment of the brain may provide an extremely advantageous milieu for an invading glioma cell. Our data show that the p75 NTR -expressing glioma cells are ligand responsive and may therefore use neurotrophins available in the brain environment to their advantage. In addition, we show that the invasive nature of glioma cells expressing p75 NTR is negated when these cells express mutant p75 NTR receptors that no longer bind to neurotrophin.
The concept of p75 NTR playing a role in migration is not unprecedented. Neural crest cells, the most extensively studied population of migrating cells in the nervous system, express p75 NTR even before they commit to any cell differentiation lineage [59] . In addition, Anton et al. [35] showed that stimulation of the p75 NTR by NGF allowed Schwann cells to migrate on peripheral nerves, and examination of p75 À/À mice showed severe impairment of Schwann cell migration, with no response to NGF [26] . More recently, the Hempstead laboratory [46] has shown that activation of p75 NTR with NGF or pro-NGF (the unprocessed, precursor form of NGF) caused migration of melanoma cells and increased expression of p75 NTR correlated with advanced stages and invasive poten- NTR expression results in decreased RhoA activity. RhoA activity was determined in U87pcDNA (pcDNA) and U87p75 (p75 NTR ) by RhoA pulldown assay using a GST fusion protein containing RBD-rhotekin that binds only to activated (GTP-bound) RhoA. Western blots using total cell lysates were performed for p75 NTR , RhoA, and b-actin (used as a protein loading control).
(D) Bar graph shows quantitation of activated RhoA (Rho-GTP) as compared to total RhoA in both U87pcDNA and U87p75. Values shown are the mean 6 SEM from four independent experiments. doi:10.1371/journal.pbio.0050212.g007
tial of melanoma brain metastasis [60] . At present, the underlying mechanism of p75-induced migration of melanoma cells is not understood; however, p75 NTR has been shown to interact with the actin cytoskeleton [46] . The small GTPase RhoA is a downstream effector of p75 NTR [27, 28] . The capability of p75 NTR to modulate the activity of RhoA provides a reasonable explanation as to how p75 NTR regulation might result in changes in cellular architecture of glioma cells. We found that concomitant with increased glioma invasion, glioma cells expressing p75 NTR showed reduced RhoA activity and striking actin rearrangement.
Previous molecular characterization has defined genetic changes between low-grade and high-grade glioma [61] [62] [63] [64] [65] [66] [67] . In addition, molecular signatures of glioblastoma subtypes have been identified, including profiles of primary and secondary glioblastoma subgroups [68] [69] [70] . On the other hand, very little is known with respect to the transcriptional profiles of invading glioma cells. Studies have been performed using laser capture microdissection in patient specimens to collect the invasive cells and the cells from the main tumor mass. Although this approach has been used successfully to identify invasion-related genes [9] , these experiments make the assumption that the invasive cells at the leading edge of the tumor have distinct profiles from the main tumor mass and that only tumor cells at the invading edge express genes important for migration and invasion. Yet, within the highly heterogeneous environment of a glioblastoma, in which there are many hypoxic and necrotic regions, it would be easy to envision that tumor cells experiencing oxidative stress would activate mechanisms enabling them to move to a more favorable environment. As such, some genes may not be identified using such an approach. Indeed, our data show that in addition to p75 NTR -expressing glioma cells at the invasive edge of patient tumors, histological analysis identified p75 NTR -positive glioma cells in regions of the tumor not adjacent to normal brain parenchyma. An alternative explanation for the appearance of p75 NTR -positive glioma cells is that p75 NTR promotes survival of glioma cells in vivo, though we did not find that p75 NTR conferred a survival advantage in vitro. Additionally, reports of ''stem-like'' cells in brain tumors suggest that brain tumors arise from the transformation of neural stem cells [71] [72] [73] , and when implanted into the brains of SCID mice, these cells form highly invasive tumors [16, 74, 75] . Whether these brain tumor stem cells express p75 NTR is an important question for future studies, especially given that nestin-positive, p75 NTR -positive cells have been identified in the subventricular zone of the adult brain [76] .
Identification of key regulatory proteins of glioma invasion is extremely important clinically because this will be used to provide therapeutically relevant targets to prevent malignant glioma recurrence at the invasive margin of gliomas [4] . Herein, we present the first evidence that p75 NTR is important in glioma migration, and the mere expression of p75 NTR is sufficient to impart a dramatic invasive behavior on genetically distinct glioblastomas. Because p75 NTR has also been implicated in the progression of melanoma, and specifically in those tumors that metastasize to the brain [33, 46, 77] , therapies that target p75 NTR , p75 NTR downstream effectors, or their ligands may not only be beneficial for malignant glioma, but may target other metastatic diseases.
Materials and Methods
Cell culture. The human glioma cell line U87 was obtained from the American Type Culture Collection (http://www.atcc.org). The human glioma cell lines U251N and SF767 were kind gifts from V. W. Yong (University of Calgary, Calgary, Alberta, Canada) and M. Berens (Barrow Neurological Institute, Phoenix, Arizona, United States), respectively. All cells were maintained in complete medium (Dulbecco's Modified Eagle's Medium [DMEM] F12 supplemented with 10% heat-inactivated fetal bovine serum, 1% antibiotic/antimycotic, 0.1 mM nonessential amino acids, 2 mM L-glutamine and 1 mM sodium pyruvate (GIBCO BRL, http://www.invitrogen.com)] at 37 8C in a humidified 5% CO 2 incubator. Cells were passaged by harvesting with trypsin when they reached 80%-90% confluence. Stable transfectants of U87 and SF767 cells were maintained in the same medium, with the addition of 400 lg/ml G418 or 200 lg/ml hygromycin, respectively (Invitrogen, http://www.invitrogen.com).
Generation of plasmids. The GFP expression vector was pGFP-N1 from Clontech (http://www.clontech.com). The human p75 NTR expression vector was constructed as described previously [46] . The expression plasmids containing the p75 NTR mutants were constructed either by subcloning of PCR fragments containing the desired p75 NTR sequences (for p75CRD 130 construct) or by PCR-based site-directed mutagenesis (for the p75CRD 105 constructs). Primers used for the construction of the mutants were: p75CRD 105 primers (sense: 59-CGG GCT CGG GCC GCT CGA GCG GCC TCG TGT TC-39; antisense: 59-GAA CAC GAG GCC GCT CGA GCG GCC CGA GCC CG-39) and template p75WT [46] ; p75CRD 130 primers (sense: 59-GAA GAT CTC CAA GGA GGC ATG CCC CAC AGG CC-39; antisense: 59-CTC ACT ATA GGT CGA CCG GAA TTC G-39) and template pT3/T7-p75. The original templates were from B. Hempstead (p75WT; Cornell University Medical College) and M. Chao (pT3/T7-p75; New York University School of Medicine, New York, New York, United States). The sequences of all the mutant expression plasmids were confirmed prior to stable transfection. The p75 NTR -specific siRNA expression vector was constructed by ligating a double-stranded hairpin oligonucleotide: 59-GAT CCG AGG ATC GGA GGC TTG TCA TTC AAG AGA TGA CAA GCC TCC GAT CCT CTT TTT TGG AAA-39, containing a p75 NTR -specific siRNA sequence (underlined), into the pSilencer 2.1-U6 hygro vector (Ambion, http://www.ambion.com). The negative control pSilencer vector, containing a random siRNA with limited homology to any known human, mouse, or rat sequences, was obtained from Ambion.
Transfection of glioma cell lines. Cells to be transfected were seeded at 2 3 10 5 cells/well of a six-well plate and incubated at 37 8C overnight in complete media. Vector DNA was introduced to the cells using FuGENE 6 transfection reagent (Roche Diagnostic, http://www. roche.com) according to the manufacturer's instructions. The cells were then incubated at 37 8C overnight; and the following day, the medium was changed to fresh complete medium containing an antibiotic (concentration determined by toxicity curve for cell line) to select for those cells that had taken up the vector. The cells were then grown under antibiotic selection until the wells were confluent. For GFP transfection, transfected cells were identified by fluorescent microscopy and GFP expression of greater than 95% was obtained by fluorescence-activated cell sorting. For p75 NTR , p75CRD 105 , p75CRD 130 , and p75 NTR -siRNA transfection, transfected cells were identified by RT-PCR and Western blot.
Animals. Six-to 8-wk-old female SCID mice were purchased from Charles River Laboratories (http://www.criver.com). The animals were housed in groups of three to five, maintained on a 12-h light/dark schedule with a temperature of 22 8C 6 1 8C and a relative humidity of 50% 6 5%. Food and water were available ad libitum. All procedures were reviewed and approved by the University of Calgary Animal Care Committee.
In vivo selection of invasive glioma cells. Actively growing U87 cells expressing GFP and neomycin resistance genes (U87GFP) were harvested by trypsinization, washed, and resuspended in sterile PBS (137 mM NaCl, 8.1 mM Na 2 HPO 4 , 2.68 mM KCl, and 1.47 mM KH 2 PO 4 [pH 7.5]). These cells were implanted intracerebrally into the right putamen of SCID mice (1 3 10 5 cells/mouse) at a depth of 3 mm through a scalp incision and a 0.5-mm burr hole made 1.5-2 mm right of the midline and 0.5-1 mm posterior to the coronal suture. Stereotactic techniques were described previously [77] . Tumor formation was allowed to proceed for 21þ days, depending on the health of the mouse and the type of cells injected. The mice were then sacrificed and the brain examined using fluorescence. The brain was divided in half coronally; one half was used for frozen sections and the other used for tissue culture. For tissue culture, the hemisphere containing the main tumor mass was separated from the contralateral hemisphere, and the two pieces were treated individually. The tissue was minced into small pieces and dissociated with trypsin and DNase I at 37 8C. The tissue suspension was then forced through a 100-lm mesh, and the resulting cell suspension was centrifuged and resuspended in complete medium containing 400 lg/ml G418 to select for the GFP-transfected tumor cells. Cells obtained from the tumor mass were labeled as ''tumor'' cells, and those from the contralateral hemisphere were labeled as ''invasive'' cells. Tumor and invasive cells were then reinoculated into SCID mice, and the procedure was repeated.
RT-PCR. Total cellular RNA was extracted from subconfluent cells using Trizol Reagent (Invitrogen) and DNase-treated using DNA-free (Ambion). The reverse transcription reaction took place in a buffer of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, and 1.5 mM MgCl 2 , and contained 3 lg of total RNA, 25 units of RNAguard RNase inhibitor, 1 mM each of deoxynucleoside triphosphates, 100 ng of pd(N) 6 Western blotting. Total cellular lysates were obtained by gentle rocking in lysis buffer (20 mM Tris [pH 8.0], 137.5 mM NaCl, 10% glycerol, 1% Nonidet P-40, 25 lg/ml aprotinin, 10 lg/ml leupeptin, 3 mM sodium orthovanadate, 1 mM PMSF) at 4 8C. Protein extracts of human glioma biopsies were obtained by immersing the samples in ice-cold extraction buffer (50 mM Tris [pH 7.6], 200 mM NaCl, 10 mM CaCl 2 , 1% Triton X-100) followed by homogenization on ice. Cellular debris was removed by centrifugation, and protein quantification was performed using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, http://www.piercenet.com). Proteins were resolved on 10% SDS-PAGE gels, and Western blots were performed using the following primary antibodies: rabbit polyclonal anti-human p75 NTR (Promega, http://www.promega.com), goat polyclonal anti-pyruvate kinase (Chemicon, http://www.chemicon.com), mouse monoclonal anti-neurofilament, 70 kDa (Chemicon), mouse monoclonal anti-glial fibrillary acid protein (ChemiconA), or mouse monoclonal anti-btubulin (Sigma-Aldrich, http://www.sigmaaldrich.com). The appropriate HRP-conjugated secondary antibody (Pierce Biotechnology) was used and visualized using enhanced chemiluminescence (Amersham Biosciences).
Flow cytometric analysis of p75 NTR expression. Cells were collected using Puck's EDTA at 37 8C and then washed in PBS containing 1 mM EDTA (PBS/EDTA). Cells were then treated with monoclonal antip75 Enzyme-linked immunosorbent assay. Cells were allowed to condition the medium for 5 d. The conditioned medium was then collected, centrifuged, and filtered through a 0.2-lm syringe filter (VWR International, http://www.vwr.com). The remaining cells were washed with ice-cold PBS, and total cellular lysates were extracted as described for Western blot. Protein quantification was performed using the BCA assay (Pierce Biotechnology) and BDNF enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, http://www. rndsystems.com) were performed as per the company protocol. Briefly, MaxiSorp ELISA plates (Nalge Nunc International, http:// www.nalgenunc.com) were coated with monoclonal anti-human BDNF (R&D Systems), nonspecific binding was blocked, and serial dilutions of recombinant human BDNF (Sigma-Aldrich), equal volumes of conditioned medium, or equal quantities of lysate were added. Bound antigen was detected using the corresponding biotinylated antibody, streptavidin HRP, and a tetramethylbenzidine substrate (R&D Systems).
Circular monolayer migration assay. Migration assays were performed using a microliter-scale radial monolayer migration assay as described by Berens et al. [78] . Briefly, ten-well Teflon-masked microscope slides were coated with 20 lg/ml laminin. Cells were seeded through a cell sedimentation manifold (Creative Scientific Methods, http://www.cre8ive-sci.com) at 2,000 cells/well to establish a circular 1-mm diameter confluent monolayer. Once the sedimentation manifolds were removed, cells were given complete medium containing the appropriate treatment. A digital image of the cells was taken (before migration ¼ 0 h) using a Zeiss Axiovert 200M inverted fluorescent microscope (Carl Zeiss, http://www.zeiss.com). The cells were then incubated in a humidified chamber at 37 8C and 5% CO 2 , and a second digital image was taken 48 h later. Best-fit circles were drawn around the area covered by the cells at the 0-h and 48-h time points and the actual cell area determined using Axiovision 4.2 imaging software (Carl Zeiss). Quantitative migration scores were calculated as the increase in the area covered by the cells beyond the initial area of the cells.
In vitro invasion assay. Matrigel (BD Bioscience, Mississauga, Ontario, Canada) was diluted with two parts of cold serum-free medium, layered onto an 8-lm pore-size transwell chamber (BD Bioscience, http://www.bdbiosciences.com), and incubated at room temperature for 1 h. The wells were then rinsed with serum-free medium. The coated chambers were placed into the wells of a 24-well tissue culture plate containing 500 ll of media with or without the desired treatment. Serum-starved cells (2.5 3 10 4 ) were seeded into each chamber, in a volume of 500 ll of the same medium contained in the bottom of the well, and incubated at 37 8C for 48 h. The medium was then removed from the chambers and cells scraped off the top of the membrane using a PBS-soaked cotton-tipped swab. Cells were fixed to the bottom of the chamber with methanol, stained in hematoxylin, and mounted on slides. Invasion was quantified by counting the stained cells adherent to the lower side of the membranes in ten fields (at 103 magnification) for each of three chambers for each condition.
In vivo studies of p75 NTR overexpression in an intracranial glioma model. Actively growing U87pcDNA, U87p75, U87CRD 105 , U87CRD 130 , U251NpcDNA, and U251Np75 cells were implanted intracerebrally into SCID mice as described previously [77] . Mice were sacrificed weekly from day 14-42. At each time point, the brains were removed, frozen in OCT compound (Tissue-Tek; Electron Microscopy Sciences, http://www.emsdiasum.com), and cryosectioned for examination by immunohistochemistry.
Immunohistochemistry. Frozen sections were air dried at room temperature, fixed with cold acetone, and then rinsed with PBS. Paraffin sections were dewaxed and rehydrated using a xylene/ ethanol series followed by rinsing with PBS. Endogenous peroxidases in the sections were inactivated with 0.075% H 2 O 2 /methanol, and nonspecific binding was blocked with 10% normal goat serum in PBS. The sections were then incubated with rabbit polyclonal anti-human p75 NTR (Promega, http://www.promega.com) or mouse monoclonal anti-human nuclei (Chemicon) in blocking buffer overnight at 4 8C. Following washing with PBS, the appropriate biotinylated secondary antibody (Vector Laboratories, http://www. vectorlabs.com) was applied. Avidin-biotin peroxidase complexes were then formed using the VECTASTAIN Elite ABC kit (Vector Laboratories) and detected by addition of SIGMAFAST DAB (3,39-diaminobenzidine tetrahydrochloride) (Sigma-Aldrich). The SIGMA-FAST DAB was converted to a brown reaction product by the peroxidase. Hematoxylin (for paraffin sections) and toluidine blue (for frozen sections) were used as nuclear counterstains. Sections were then dehydrated in an ethanol/xylene series and mounted with Entellan (Electron Microscopy Sciences).
Immunocytochemistry. Coverslips were coated with a Collagen I (3 mg/ml; Vitrogen 100; Cohesion Technologies, http://www. cohesiontech.com) and incubated overnight at 37 8C. Excess collagen solution was aspirated, and cells were plated at 2 3 10 5 /mL in DMEM culture medium (DMEM with 10% FBS, 6 mM L-glutamine, 100 lM nonessential amino acids, 1 mM sodium pyruvate, 400 lg/ml G418) and allowed to equilibrate overnight at 37 8C, 5% CO 2 . Coverslips were then rinsed twice with PBS, fixed in 3.7% formaldehyde diluted in PBS for 10 min, and rinsed twice with PBS. Unpolymerized actin was extracted for 3 min in CSK buffer (10 mM MES [pH 6.1], 138 mM KCl, 3 mM MgCl 2 , 2 mM EGTA, 320 mM sucrose, 0.1% Triton X-100) followed by two rinses with PBS. Alexa Fluor 568 phalloidin (Invitrogen) was diluted 1:40 in 1% BSA/PBS and 200 ll of this solution was added to each coverslip for 20 min at room temperature. Coverslips were rinsed twice with PBS, counterstained with a 500 nM solution of DAPI for 3 min, mounted in glycerol, and imaged with an Olympus IX70 Delta Vision RT Microscope (http://www.olympus.co. jp/en/) and the SoftWoRx software package.
Tumor tissue. Tumor and normal tissues were obtained from the Canadian Brain Tumor Tissue Bank in London, Ontario, and Foothills Hospital, Calgary, Alberta. Briefly, tissue was taken during surgery while patients were under a general anesthetic, and was placed immediately in liquid nitrogen and stored at À80 8C or placed in culture medium for establishment of short-term cultures. An institutional ethics board approved the collection and use of all of the surgical tissue used, and all of the patients gave signed informed consent. The following tissues were studied: 20 GBMs, eight anaplastic astrocytomas, one anaplastic oligodendroglioma, five astrocytomas, five mixed oligoastrocytomas, one oligodendroglioma, and five controls obtained during nontumor brain surgery.
Short-term culture of primary human glioma cells. Operative samples of human gliomas were obtained during brain tumor surgery and transported to the laboratory in culture medium. Short-term cultures were then established. Briefly, necrotic and connective tissue and any blood clots were removed using forceps, and the remaining tissue was washed in PBS and cut into pieces of approximately 1 mm 2 . The tissue was then incubated for 30 min at 37 8C in an enzyme cocktail of trypsin (0.25%) and DNase I (10 lg/ml) in PBS. The digested tissue was strained through a 100-lm mesh and washed with PBS. The cells were then pelleted and washed with DMEM-F12 media. Following lysis of red blood cells, the remaining cells were washed with PBS, pelleted, resuspended in complete media containing 20% FBS, and plated.
Transwell motility assay of primary human glioma cells. Primary human glioma cells cultured for less than 3 wk were ''serum-starved'' by incubating them in medium containing only 1% FBS for 2 h at 37 8C and 5% CO 2 . Cells were then released from the culture dish using Puck's EDTA (1 mM EDTA, 10 mM HEPES, 5 mM KCl, 140 mM NaCl, 4 mM NaHCO 3 , and 6 mM dextrose [pH 7.3]) at 37 8C. Cells (2.5 3 10 4 ) suspended in 1% FBS medium were plated in eight-well chamber slides (Nunc) and transwell chambers (Costar) coated with 20 lg/ml laminin. Medium containing 1% FBS was placed below the chamber. The cells were incubated at 37 8C and 5% CO 2 for 6 h. The medium was then removed from the chambers, and cells were fixed with 4% paraformaldehyde. The cells were then stained for human p75 NTR , as described for immunohistochemical staining, and counterstained with hematoxylin. In the transwell chamber, cells that did not migrate were scraped off the top of the membrane using a cotton-tipped swab. Migration was quantified by counting the p75 NTR -positive (brown) and p75 NTR -negative (blue) cells in the original population (on the slide) or in the migratory population (adherent to the under side of the transwell membrane) in five fields (at 203 magnification) for each of four chambers. Figure S1 . In Vivo-Selected U251 Invasive Cells Express p75 NTR U251 human glioma GFP-expressing cell line was implanted into the brains of SCID mice; and 4-6 wk later, the mice were sacrificed. The ipsilateral side of the brain (containing a grossly visible tumor) was separated from the contralateral side (containing only isolated invasive glioma cells) and both were grown in culture. These noninvasive (tumor [U251T]) and highly invasive (invasive [U251R]) cells were reimplanted and the process repeated to select for increasingly noninvasive or invasive glioma cells. Through the serial in vivo selection, highly invasive U251 glioma cells were isolated. Western-blot analysis of p75 NTR expression in tumor and invasive U251 human glioma cells shows a dramatic increase in endogenous p75 NTR expression in the U251 invasive cells as compared to the U251 tumor cells. U87 tumor (U87T) and invasive (U87R) cells were used for comparison (A). The invasive U251 cells, which endogenously express p75 
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